Know Cancer

or
forgot password

Multicenter Phase I/II Study of Radioimmunotherapy With 90Y-ibritumomab Tiuxetan in a Nonmyeloablative Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation From HLA-identical Donors in Patients With Advanced Non-Hodgkin Lymphoma


Phase 1/Phase 2
18 Years
70 Years
Not Enrolling
Both
Non-Hodgkin Lymphoma

Thank you

Trial Information

Multicenter Phase I/II Study of Radioimmunotherapy With 90Y-ibritumomab Tiuxetan in a Nonmyeloablative Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation From HLA-identical Donors in Patients With Advanced Non-Hodgkin Lymphoma


Inclusion Criteria:



- Patients with advanced CD20+ NHL (non-Hodgkin lymphoma) relapsed after at least two
preceding chemotherapy regimens including treatment with rituximab or with relapse
after autologous HCT (hematopoietic cell transplantation)

The following entities of lymphomas can be included in Arm A of the protocol:

Arm A:

- Small lymphocytic lymphoma (SLL/CLL)

- Mantle cell lymphoma (MCL)

- Follicular lymphoma Grade 1-2

- Marginal zone lymphoma (MZL)

- Extranodal (MALT lymphoma)

- Nodal (Monocytoid B-cell lymphoma)

- Splenic

The following lymphoma entities can be included in Arm B of the protocol:

Arm B:

- Diffuse large B-cell lymphoma/follicular lymphoma grade 3

- Grade 3 follicular lymphoma

- Blastic mantle cell lymphoma

- Mediastinal B-cell lymphoma

- Age > 18, < 70 years

- Karnofsky score > 60%

- HLA-identical related or unrelated donor

- CD20+ lymphoma cells on biopsy or peripheral blood

- Disease stage at inclusion: CR, PR or SD

Exclusion Criteria:

- Patients with rapidly progressive disease

- Less than 3 months after preceding HCT

- CNS involvement with disease

- Fungal infections with radiological progression after receipt of amphotericin B or
active triazole for greater than 1 month

- Liver function abnormalities with bilirubin > 2 mg/dL and elevation of transaminases
higher than 2x upper limit of normal

- Chronic active viral hepatitis

- Ejection fraction < 40% on echocardiography

- Patients with > grade II hypertension by CTC criteria

- Creatinine clearance < 50 ml/min

- Respiratory failure necessitating supplemental oxygen or DLCO < 30%

- Allergy against murine antibodies

- HIV infection

- Female patients who are pregnant or breast feeding, or adults of reproductive
potential not employing an effective method of birth control during study treatment
and for at least 12 months thereafter. (Women of childbearing potential must have a
negative serum pregnancy test at study entry.)

- Patients with pleural effusion or ascites

- Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes,
congestive heart failure, myocardial infarction within 6 months prior to the study,
unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled
infection) which could compromise participation in the study

- Patients who received any investigational drugs less than 4 weeks before entry in
this study or who have not as yet recovered from the toxic effects of such therapy

- Patients who underwent surgery within 4 weeks of entering the study or patients who
have not as yet recovered from the side-effects of such treatment

- Patients with a history of psychiatric illness or condition which could interfere
with their ability to understand the requirements of the study (this includes
alcoholism/drug addiction)

- Patients unwilling or unable to comply with the protocol

- Unable to give informed consent

- Enrollment in another trial interfering with the endpoints of this study

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

treatment related toxicity

Principal Investigator

Wolfgang A Bethge, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Medical Center University of Tuebingen

Authority:

Germany: Paul-Ehrlich-Institut

Study ID:

2005-002206-37

NCT ID:

NCT00302757

Start Date:

March 2006

Completion Date:

Related Keywords:

  • Non-Hodgkin Lymphoma
  • NHL
  • low and high grade non-Hodgkin lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location